Michael CPA - Nuvectis Pharma Vice Finance

NVCT Stock

USD 9.35 0.39 4.35%

Executive

Michael CPA is Vice Finance of Nuvectis Pharma

Age	49
Address	1 Bridge Plaza, Fort Lee, NJ, United States, 07024
Phone	201 614 3150
Web	https://www.nuvectis.com

Nuvectis Pharma Management Efficiency

The company has return on total asset (ROA) of (0.6565) % which means that it has lost $0.6565 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7341) %, meaning that it created substantial loss on money invested by shareholders. Nuvectis Pharma's management efficiency ratios could be used to measure how well Nuvectis Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.07 in 2025. Return On Capital Employed is likely to drop to -1.77 in 2025. Change To Liabilities is likely to gain to about 5 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 5.4 M in 2025.

Compare Nuvectis Pharma to Peers

Predict price of Nuvectis Pharma

Nuvectis Pharma currently holds 8.89 M in liabilities. Nuvectis Pharma has a current ratio of 5.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Nuvectis Pharma's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives			EXECUTIVE Age
	MBA MD	Celcuity LLC	N/A
	MBA III	Celcuity LLC	64
	John JD	Edgewise Therapeutics	61
	BSc MD	Aerovate Therapeutics	N/A
	Leonard MD	C4 Therapeutics	63
	Jeff Boerneke	Gossamer Bio	N/A
	Christian JD	Gossamer Bio	58
	Douglas Kling	NewAmsterdam Pharma	52
	Christopher Dinsmore	Kronos Bio	57
	DO Sr	Larimar Therapeutics	63
	Paige Mahaney	C4 Therapeutics	N/A
	Roy Pollock	C4 Therapeutics	N/A
	Caryn Peterson	Gossamer Bio	66
	John Moore	Edgewise Therapeutics	60
	Robert Smith	Gossamer Bio	56
	Susan Fischer	Aerovate Therapeutics	N/A
	Daniel George	Anebulo Pharmaceuticals	55
	Samantha Vuksanic	Ikena Oncology	N/A
	Bob Laughner	Orchestra BioMed Holdings	N/A
	Robert Richard	Lyra Therapeutics	67
	Richard MD	Lyra Therapeutics	61

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company was incorporated in 2020 and is based in Fort Lee, New Jersey. Nuvectis Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. Nuvectis Pharma (NVCT) is traded on NASDAQ Exchange in USA. It is located in 1 Bridge Plaza, Fort Lee, NJ, United States, 07024 and employs 13 people. Nuvectis Pharma is listed under Biotechnology category by Fama And French industry classification.

Management Performance

	Return On Equity	-1.73
	Return On Asset	-0.66

Nuvectis Pharma Leadership Team

Elected by the shareholders, the Nuvectis Pharma's board of directors comprises two types of representatives: Nuvectis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nuvectis. The board's role is to monitor Nuvectis Pharma's management team and ensure that shareholders' interests are well served. Nuvectis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nuvectis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Shay Shemesh, Executive CoFounder
	Michael CPA, Vice Finance
	Ron MBA, Chairman, CoFounder
	Enrique Poradosu, Executive CoFounder

Nuvectis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nuvectis Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-1.73
	Return On Asset	-0.66
	Current Valuation	202.28 M
	Shares Outstanding	23.39 M
	Shares Owned By Insiders	45.35 %
	Shares Owned By Institutions	6.92 %
	Number Of Shares Shorted	1.56 M
	Price To Book	22.73 X
	EBITDA	(22.9 M)
	Net Income	(19 M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Nuvectis Stock Analysis

When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC